Oragenics, Inc. (OGEN)
USD 0.17
(-8.76%)
USD 0.17
(-8.76%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.96 Million USD | -66.35% |
| 2022 | 14.75 Million USD | -47.72% |
| 2021 | 28.23 Million USD | 51.13% |
| 2020 | 18.68 Million USD | -5.43% |
| 2019 | 19.75 Million USD | -10.42% |
| 2018 | 22.04 Million USD | 205.61% |
| 2017 | 7.21 Million USD | 67.43% |
| 2016 | 4.3 Million USD | -25.43% |
| 2015 | 5.77 Million USD | -48.09% |
| 2014 | 11.13 Million USD | -33.86% |
| 2013 | 16.83 Million USD | 60.48% |
| 2012 | 10.48 Million USD | 727.82% |
| 2011 | 1.26 Million USD | -26.67% |
| 2010 | 1.72 Million USD | -46.06% |
| 2009 | 3.2 Million USD | 100.92% |
| 2008 | 1.59 Million USD | 38.45% |
| 2007 | 1.15 Million USD | -28.3% |
| 2006 | 1.6 Million USD | -25.18% |
| 2005 | 2.14 Million USD | -51.94% |
| 2004 | 4.46 Million USD | 22.33% |
| 2003 | 3.65 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 3.53 Million USD | -28.84% |
| 2024 Q2 | 2.7 Million USD | -23.32% |
| 2023 Q4 | 4.96 Million USD | -37.13% |
| 2023 FY | 4.96 Million USD | -66.35% |
| 2023 Q1 | 12.12 Million USD | -17.81% |
| 2023 Q2 | 8.46 Million USD | -30.22% |
| 2023 Q3 | 7.89 Million USD | -6.68% |
| 2022 Q1 | 22.2 Million USD | -21.35% |
| 2022 Q3 | 15.04 Million USD | -18.54% |
| 2022 FY | 14.75 Million USD | -47.72% |
| 2022 Q4 | 14.75 Million USD | -1.88% |
| 2022 Q2 | 18.46 Million USD | -16.84% |
| 2021 Q4 | 28.23 Million USD | -9.2% |
| 2021 FY | 28.23 Million USD | 51.13% |
| 2021 Q3 | 31.09 Million USD | -11.79% |
| 2021 Q2 | 35.24 Million USD | -5.67% |
| 2021 Q1 | 37.36 Million USD | 100.03% |
| 2020 Q4 | 18.68 Million USD | 65.58% |
| 2020 FY | 18.68 Million USD | -5.43% |
| 2020 Q3 | 11.28 Million USD | 5.13% |
| 2020 Q2 | 10.73 Million USD | -31.04% |
| 2020 Q1 | 15.56 Million USD | -21.22% |
| 2019 FY | 19.75 Million USD | -10.42% |
| 2019 Q1 | 31.3 Million USD | 41.99% |
| 2019 Q2 | 26.93 Million USD | -13.98% |
| 2019 Q3 | 23.65 Million USD | -12.18% |
| 2019 Q4 | 19.75 Million USD | -16.49% |
| 2018 Q4 | 22.04 Million USD | 41.93% |
| 2018 Q2 | 5.2 Million USD | -5.2% |
| 2018 Q1 | 5.49 Million USD | -23.85% |
| 2018 FY | 22.04 Million USD | 205.61% |
| 2018 Q3 | 15.53 Million USD | 198.27% |
| 2017 Q2 | 4.57 Million USD | 94.71% |
| 2017 FY | 7.21 Million USD | 67.43% |
| 2017 Q4 | 7.21 Million USD | 40.49% |
| 2017 Q3 | 5.13 Million USD | 12.19% |
| 2017 Q1 | 2.35 Million USD | -45.44% |
| 2016 Q4 | 4.3 Million USD | -20.14% |
| 2016 FY | 4.3 Million USD | -25.43% |
| 2016 Q1 | 3.95 Million USD | -31.52% |
| 2016 Q2 | 6.13 Million USD | 55.09% |
| 2016 Q3 | 5.39 Million USD | -12.08% |
| 2015 Q2 | 8.69 Million USD | -10.92% |
| 2015 FY | 5.77 Million USD | -48.09% |
| 2015 Q4 | 5.77 Million USD | -21.81% |
| 2015 Q3 | 7.38 Million USD | -15.01% |
| 2015 Q1 | 9.76 Million USD | -12.31% |
| 2014 Q1 | 15.14 Million USD | -10.04% |
| 2014 Q2 | 13.33 Million USD | -11.92% |
| 2014 FY | 11.13 Million USD | -33.86% |
| 2014 Q4 | 11.13 Million USD | -9.51% |
| 2014 Q3 | 12.3 Million USD | -7.75% |
| 2013 FY | 16.83 Million USD | 60.48% |
| 2013 Q4 | 16.83 Million USD | 90.94% |
| 2013 Q3 | 8.81 Million USD | 24.66% |
| 2013 Q1 | 8.82 Million USD | -15.88% |
| 2013 Q2 | 7.07 Million USD | -19.85% |
| 2012 Q4 | 10.48 Million USD | -16.65% |
| 2012 Q2 | 1.98 Million USD | 2.14% |
| 2012 Q1 | 1.94 Million USD | 53.23% |
| 2012 FY | 10.48 Million USD | 727.82% |
| 2012 Q3 | 12.58 Million USD | 534.61% |
| 2011 Q2 | 1.3 Million USD | 10.95% |
| 2011 FY | 1.26 Million USD | -26.67% |
| 2011 Q1 | 1.17 Million USD | -31.81% |
| 2011 Q3 | 1.22 Million USD | -5.97% |
| 2011 Q4 | 1.26 Million USD | 3.08% |
| 2010 Q1 | 2.22 Million USD | -30.43% |
| 2010 FY | 1.72 Million USD | -46.06% |
| 2010 Q4 | 1.72 Million USD | -34.57% |
| 2010 Q3 | 2.64 Million USD | 57.38% |
| 2010 Q2 | 1.67 Million USD | -24.7% |
| 2009 Q4 | 3.2 Million USD | 196.58% |
| 2009 FY | 3.2 Million USD | 100.92% |
| 2009 Q1 | 499.35 Thousand USD | -68.68% |
| 2009 Q2 | 2.12 Million USD | 325.97% |
| 2009 Q3 | 1.07 Million USD | -49.23% |
| 2008 Q2 | 4.26 Million USD | 67.0% |
| 2008 FY | 1.59 Million USD | 38.45% |
| 2008 Q4 | 1.59 Million USD | -51.2% |
| 2008 Q3 | 3.26 Million USD | -23.39% |
| 2008 Q1 | 2.55 Million USD | 121.76% |
| 2007 Q4 | 1.15 Million USD | -33.62% |
| 2007 FY | 1.15 Million USD | -28.3% |
| 2007 Q2 | 1.06 Million USD | -32.87% |
| 2007 Q1 | 1.59 Million USD | -0.82% |
| 2007 Q3 | 1.73 Million USD | 62.23% |
| 2006 Q2 | 1.96 Million USD | 3.3% |
| 2006 Q1 | 1.9 Million USD | -11.2% |
| 2006 FY | 1.6 Million USD | -25.18% |
| 2006 Q4 | 1.6 Million USD | 9.22% |
| 2006 Q3 | 1.47 Million USD | -25.33% |
| 2005 Q3 | 2.15 Million USD | -30.36% |
| 2005 Q4 | 2.14 Million USD | -0.44% |
| 2005 Q2 | 3.09 Million USD | -18.41% |
| 2005 FY | 2.14 Million USD | -51.94% |
| 2005 Q1 | 3.79 Million USD | -15.05% |
| 2004 Q3 | 4.8 Million USD | -10.45% |
| 2004 FY | 4.46 Million USD | 22.33% |
| 2004 Q1 | 6.1 Million USD | 67.11% |
| 2004 Q2 | 5.36 Million USD | -11.99% |
| 2004 Q4 | 4.46 Million USD | -7.12% |
| 2003 Q4 | 3.65 Million USD | 100.52% |
| 2003 Q2 | 1.93 Million USD | 0.0% |
| 2003 FY | 3.65 Million USD | 0.0% |
| 2003 Q3 | 1.82 Million USD | -6.09% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AIM ImmunoTech Inc. | 19.38 Million USD | 74.375% |
| Ampio Pharmaceuticals, Inc. | 5.73 Million USD | 13.418% |
| Armata Pharmaceuticals, Inc. | 109.96 Million USD | 95.484% |
| Actinium Pharmaceuticals, Inc. | 81.44 Million USD | 93.902% |
| Azitra, Inc. | 5.11 Million USD | 2.916% |
| Can-Fite BioPharma Ltd. | 9.98 Million USD | 50.282% |
| Chromocell Therapeutics Corporation | 96.39 Thousand USD | -5052.281% |
| Calidi Biotherapeutics, Inc. | 10.01 Million USD | 50.431% |
| CEL-SCI Corporation | 30.52 Million USD | 83.732% |
| iBio, Inc. | 28.73 Million USD | 82.716% |
| Lineage Cell Therapeutics, Inc. | 101.01 Million USD | 95.084% |
| MAIA Biotechnology, Inc. | 7.56 Million USD | 34.367% |
| Matinas BioPharma Holdings, Inc. | 65.57 Million USD | 92.427% |
| Navidea Biopharmaceuticals, Inc. | 4.37 Million USD | -13.604% |
| NovaBay Pharmaceuticals, Inc. | 9.03 Million USD | 45.026% |
| NanoViricides, Inc. | 12.82 Million USD | 61.27% |
| BiomX Inc. | 58.15 Million USD | 91.46% |
| BiomX Inc. | 58.15 Million USD | 91.46% |
| Protalix BioTherapeutics, Inc. | 84.43 Million USD | 94.118% |
| Palatin Technologies, Inc. | 10.74 Million USD | 53.768% |
| Scorpius Holdings, Inc. | 51.03 Million USD | 90.269% |
| Theriva Biologics, Inc. | 60.21 Million USD | 91.752% |